BCEL

In a report issued on June 1, Joel Beatty from Robert W. Baird maintained a Buy rating on Atreca (BCEL – Research Report), with a price target of $9.00. The company's shares closed last Thursday at $1.56, close to its 52-week low of $1.52. According to TipRanks.com, Beatty is a 1-star analyst with an average return of -1.1% and a 41.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Atreca is a Strong Buy with an average price target of $17.40, implying a 1001.3% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/robert-w-baird-thinks-atrecas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral